Altered clinical course of malignant melanoma in HIV-positive patients.
OBJECTIVE
To determine whether the natural history of melanoma is different in patients who test positive for human immunodeficiency virus (HIV) compared with matched control subjects.


METHODS
Retrospective cohort analysis.


METHODS
Ambulatory care at 2 university-affiliated medical centers.


METHODS
Each HIV-positive melanoma patient (n = 17) was randomly matched with 2 HIV-negative patients (HIV status unknown, but without risk factors for HIV) based on the melanoma subtype, tumor thickness, Clark level, tumor location, and sex and age of the patient.


METHODS
Disease-free survival and overall survival of HIV-positive and HIV-negative melanoma patients were compared using a matched-pairs analysis. CD4 cell counts were recorded at the time of melanoma diagnosis and disease recurrence.


RESULTS
Melanoma patients who were HIV positive had a significantly shorter disease-free survival (P =.03) and overall survival (P =.045) compared with HIV-negative melanoma patients by matched-pairs analysis. There was an inverse relationship between CD4 cell counts and time to first melanoma recurrence.


CONCLUSIONS
The natural history of malignant melanoma in HIV-positive patients is more aggressive compared with matched HIV-negative melanoma patients. Altered immune response and comorbid disease may play a role in the poor clinical outcome of HIV-positive patients. These findings have important implications in the management of melanoma in the setting of HIV disease.
Rodrigues
Lori K E
LK
University of California, San Francisco, Melanoma Center, UCSF Comprehensive Cancer Center, San Francisco, CA 94115, USA.
Klencke
Barbara J
BJ
Vin-Christian
Kirsten
K
Berger
Timothy G
TG
Crawford
Richard I
RI
Miller
James R
JR
Ferreira
Carlos M M
CM
Nosrati
Mehdi
M
Kashani-Sabet
Mohammed
M
D000328:Adult; D017677:Age Distribution; D000368:Aged; D001707:Biopsy, Needle; D016022:Case-Control Studies; D015331:Cohort Studies; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D018023:HIV Seronegativity; D006679:HIV Seropositivity; D006801:Humans; D008297:Male; D008545:Melanoma / Q000401:mortality* / Q000473:pathology* / Q000503:physiopathology; D008875:Middle Aged; D009367:Neoplasm Staging; D011336:Probability; D011379:Prognosis; D012016:Reference Values; D012189:Retrospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D017678:Sex Distribution; D012878:Skin Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000503:physiopathology; D018709:Statistics, Nonparametric; D015996:Survival Rate